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Abstract 
Background: Small vessel disease (SVD) and Alzheimer disease (AD) are two common causes of 
cognitive impairment and dementia, traditionally considered as distinct processes. We explored the 
relationship between radiological features suggestive of AD and SVD, and investigated the 
association of each of these features with cognitive status at one year in patients with stroke or 
transient ischaemic attack. 
Methods: Anonymised data were accessed from the Virtual International Stroke Trials Archive 
(VISTA). We rated medial temporal lobe atrophy (MTA; a marker of AD) and markers of SVD 
using validated ordinal visual scales. Cognitive status was evaluated with Mini Mental State 
Examination (MMSE) one year after the index stroke. We used logistic regression models to 
investigate independent associations between: 1-baseline SVD features and MTA, and 2-all baseline 
neuroimaging features and cognitive status one year post-stroke. 
Results: We included 234 patients, mean (±SD) age=65.7±13.1 years, 145 (62%) male. Moderate to 
severe MTA was present in 104 (44%) patients. SVD features were independently associated with 
MTA (p<0.001). After adjusting for age, sex, disability after stroke, hypertension and diabetes 
mellitus, MTA was the only radiological feature independently associated with cognitive 
impairment, defined using thresholds of MMSE≤26 (OR=1.94; 95% CI=1.28-2.94) and MMSE≤23 
(OR=2.31; 95% CI=1.48-3.62). 
Conclusion: In patients with ischaemic cerebrovascular disease, SVD features are associated with 
MTA, which is a common finding in stroke survivors. SVD and AD-type neurodegeneration co-
exist, but the AD marker MTA, rather than SVD markers, is associated with post stroke cognitive 
impairment.  
 
 
Introduction 
Dementia is a major public health issue, affecting approximately 47 million people worldwide, by 
2030, this figure will increase to approximately 75 million 1. After Alzheimer disease (AD), vascular 
dementia (VaD) is the second most common type of dementia. The pathological processes that 
contribute to AD and VaD differ, with primary neuronal degeneration considered to be the 
pathological process that contributes to AD, and cerebral small vessel disease (SVD) a major 
contributor to VaD. Medial temporal lobe atrophy (MTA) is a major neurodegenerative dementia 
marker that is traditionally associated with the clinical diagnosis of AD2. In contrast, the radiological 
features of SVD encompass a wide range of imaging phenotypes, ranging from white matter changes 
(WMCs), to lacunar infarcts and enlarged perivascular spaces (EPVS)3.   
AD and SVD are usually considered distinct entities with differing neuroradiological appearances. 
The concept of exclusive categorizations of AD and vascular dementia (VaD) has been challenged.  
A recent scientific statement underscored the importance of the vascular contribution to all cause 
cognitive impairment and dementia4, while observational data suggest that vascular risk factors such 
as hypertension and diabetes may play an important role in pathogenesis and progression of AD5,6,7.  
Following stroke, a third of patients develop dementia, and up to two thirds have some degree of 
persisting cognitive impairment8. Establishing the pathogenesis of post stroke cognitive impairment 
may allow for development of targeted therapy. The impaired cognition that follows stroke is 
traditionally considered to be of vascular origin, however it seems plausible that a substantial 
proportion with post stroke cognitive impairment may have co-existing AD type pathology. In this 
regard, the evidence about vascular and neurodegenerative contribution to cognitive impairment after 
stroke is not definitive, and the overlap between such contributors remains overlooked9. Therefore, 
our aim was to evaluate the relationship between neuroimaging markers of AD, SVD and cognition 
in a cohort of patients with ischaemic stroke, extending the existing evidence. 
Our specific objectives were to: 
a) describe the association between SVD and an exemplar AD neuroimaging marker (MTA) 
b) describe the association between these neuroimaging features and cognitive status one year 
after the index stroke.   
 
Methods 
Participants 
We conducted individual patient level data analyses using the Virtual International Stroke Trial 
Archive (VISTA). VISTA is an academic collaboration that provides access to existing anonymised 
trial data to perform exploratory analyses; to allow hypothesis testing and to inform the design of 
future clinical trials10.  
From the VISTA resource, we included those patients with diagnosis of ischaemic stroke and 
transient ischaemic attack (TIA), where magnetic resonance (MR) imaging of brain and evaluation of 
cognitive status (e.g., cognitive scales, clinical evaluation) were available. All included trials 
required valid consent. Clinical variables of interest included: age, sex, clinical history of 
hypertension, diabetes mellitus, atrial fibrillation, hypercholesterolemia, peripheral artery disease, 
ischaemic heart disease, cigarette smoke exposure and depression (all defined as per parent trials). 
Included participants had vascular, laboratory and cardiac investigation data available; 
characterisation of stroke aetiology was assessed according to the method described in the Trial of 
Org 10172 (TOAST)11. Function was assessed at baseline (i.e. after the index stroke) and quantified 
using the Oxford Handicap Scale (OHS)12; and used as a proxy for stroke severity. OHS is a 
derivative of the modified Rankin Scale, which is the most common outcome measure in stroke 
trials.  
Imaging analysis 
A stroke neurologist trained in MR assessment and blinded to clinical data (FA) rated all the 
available scans (T1, T2, FLAIR sequences). SVD features were rated according to STRIVE 
(STandards for ReportIng Vascular changes on nEuroimaging) recommendations13. Where the index 
infarct was too large to allow the rating of the SVD features, we performed SVD ratings only in the 
non-affected hemisphere. We defined lacunes as round shaped cerebrospinal fluid isointense lesions 
measuring ≤20 mm in diameter on axial section in the white matter, basal ganglia or brainstem as 
seen on T1, T2 or FLAIR sequences. We graded white matter hyperintensities according to Van 
Swieten scale14 as 0-4, combining the ratings in the anterior and posterior periventricular white 
matter. Brain atrophy was defined as central and cortical, and rated as none, moderate and severe 
against a reference MR brain template15. Enlarged perivascular spaces (EPVS) were defined as ≤2 
mm round or linear cerebrospinal fluid isointense lesions (T2 hyperintense and T1/FLAIR 
hypointense). We separately rated EPVS in basal ganglia and centrum semiovale using a 5-point 
ordinal scale16 as follows:  0=no EPVS, 1=1-10 EPVS, 2=11 to 20, EPVS, 3=21 to 40 EPVS, and 4= 
>40 EPVS. As a marker of neurodegeneration classically seen in AD, we rated MTA with coronal T1 
weighted sequences in 0-4 with a validated visual scale2 and against a reference template.  
Cognitive status 
We included studies with cognitive assessment after one year the index stroke. Cognitive impairment 
was assessed using the Mini Mental State Examination (MMSE)17. We defined cognitive impairment 
as MMSE≤2618. We used an alternative threshold, said to be more specific to dementia MMSE≤23. 
We excluded patients with a baseline diagnosis of dementia from our analysis (n=6). 
Statistical analysis 
After taking into account the distribution of data, we used Spearman’s rank correlation coefficient to 
evaluate the relationship between each of the SVD MR features and MTA. We described MMSE 
scores, stratified by MTA grading and analyzed between-group differences with Kruskal-Wallis test. 
To assess multivariable association with MTA, we used logistic regression. We dichotomized MTA 
into groups of: 0-1 (none to mild MTA) vs 2-4 (moderate to severe). We described univariate 
associations between SVD features and dichotomized MTA. For our multivariable models, we 
retained statistically significant (p<0.1) variables from the univariate analysis. We also included 
variables with face validity or where previous work has suggested an association with cognition, 
such as age, sex, history of hypertension and history of diabetes.  
We described univariate associations between all neuroimaging features (both SVD and MTA, 
considered as ordinal scales) and cognitive status. We similarly created a multivariate model 
comprising significant and known associated variables as described previously.  For multivariate 
models we described adjusted odds-ratios (OR) and their 95% confidence intervals (CI); statistical 
significance was defined as p<0.05. 
 
Results 
A total of 234 patients had full clinical, radiological and cognitive data. Mean (±SD) age was 65.7 
(±13.1), 145 patients (62%) were male. One hundred and ninety five patients had ischaemic stroke as 
index event (83%), of whom 94 (40%) had lacunar stroke subtype (Table 1).  
One hundred and four (44%) patients were assessed to have moderate to severe MTA (a score of 2 to 
4). Compared to patients with no to mild MTA, those with moderate to severe MTA were older (60.2 
vs 70.5 years, p<0.001), more frequently had a history of hypertension (73% vs 87%, p<0.012), had 
a higher grade of disability at baseline (median OHS=1 vs 2, p<0.001) and more frequently had 
evidence of  our chosen SVD neuroimaging features (all P<0.001).(Table 1)  
MTA had positive correlations with all SVD features. MTA was most closely related with central 
brain atrophy (ρ=0.64, p<0.001) and white matter changes (ρ=0.60, p<0.001), the weakest 
correlations were with number of lacunes (ρ=0.32, p<0.001) and centrum semiovale EPVS (ρ=0.35, 
p<0.001).(Table 2)  
In logistic regression models, after adjusting for age, sex, hypertension and diabetes mellitus, several 
radiological features of SVD remained independently associated with MTA (Table 3). Only the 
association between centrum semiovale EPVS and MTA failed to reach statistical significance in our 
sample (OR=1.47; 95% CI=0.99-2.18, p=0.057), even though the magnitude of effect was similar to 
the unadjusted analysis.  
One year after index stroke, 101 (43%) patients had cognitive impairment as defined by MMSE≤26, 
whereas 67 (29%) had MMSE≤23, suggestive of dementia. Distribution of MMSE scores among 
MTA grades showed a decline in cognitive performance with increasing severity of MTA (p<0.001, 
Figure 1). In the univariable logistic regression models, all the radiological variables were associated 
with development of cognitive impairment at one year, and only lacunes were not significantly 
associated with dementia. However, after adjustment for age, sex, disability status, hypertension and 
diabetes mellitus, only MTA remained independently associated with MMSE≤26 (OR=1.94 per 
point increase in MTA score; 95% CI=1.28-2.94) and with MMSE≤23 (OR=2.31; 95% CI=1.48-
3.62).    
 
Discussion 
We found that MTA is a common finding in clinical stroke trial population, and has important 
implications for cognition status at 1 year post-stroke. MTA and SVD may coexist, but MTA seems 
to have a stronger association with cognitive status than SVD markers.  
To date, few studies have specifically addressed the potential overlap between radiological markers 
of SVD and neurodegeneration markers in a population of patients with ischaemic stroke. In our 
clinical trial based population, MTA was present in 40% of patients, a proportion comparable with 
previous studies19,20,21. We found that MTA strongly correlated with brain features that may be seen 
in any dementia process, for example atrophy. However, we also demonstrated correlation of MTA 
with neuroimaging features usually described as exclusively relating to small vessel cerebrovascular 
disease, for example lacunes and basal ganglia EPVS. The independent association between SVD 
radiological markers and MTA alludes to a potential overlap between neurodegenerative and 
neurovascular pathology. Other groups have also reported this shared pathology, with WMCs 
described in patients with AD22 and MTA present in more than half of elderly stroke survivors20,21 
and in patients with diagnosis of vascular dementia23.  
In our study, MTA severity was independently associated with cognitive impairment and dementia.  
It is perhaps unsurprising that small vessel cerebrovascular features have limited association with 
cognition after correction for vascular risk factors, as SVD is so closely related to hypertension and 
diabetes mellitus. Our results support that SVD and AD frequently co-exist but are not synonymous, 
as MTA still demonstrated cognitive association even after correction for vascular risk factors. Our 
results are in line with a previous study that showed MTA rather than white matter changes as the 
strongest marker of long-term memory function after stroke24. 
However, we did not have pre-stroke assessment of cognitive status. It is possible that some 
participants had unrecognised cognitive issues, given the high prevalence of MTA atrophy. 
However, it seems unlikely that many of the participants will have had frank dementia at study 
recruitment. Furthermore, there is no validated assessment of pre-stroke cognition25. Pre-stroke 
dementia may not be diagnosed till after presenting to stroke services and it could be argued that 
patients with MTA had AD prior to their index stroke event. This argument is not supported by our 
data, despite almost half of our included population exhibiting moderate to severe MTA, only six 
patients had a clinical diagnosis of dementia at baseline assessment. At one year, around a third of 
the study patients had MMSE≤23, suggestive of dementia. This finding suggests that pre-existing 
MTA may act as a marker of “brain frailty” pre-disposing a person to development of long term 
cognitive deficits. In this cognitively vulnerable state, incident stroke may be a sufficient cognitive 
“stressor” to lead to clinical cognitive impairment. MTA may therefore represent a useful in vivo 
biomarker to stratify stroke patients in clinical trials investigating cognitive outcomes. Such trials 
should include also MTA assessment as baseline radiological marker.  
The strengths of our study are the standardized assessment of radiological variables with extensively 
validated radiological scales and the reproducibility of our methodology in clinical practice. The 
validated visual ratings we used are widely adopted, and cognitive function was screened using the 
MMSE, which is widely used by many stroke physicians. Although we recognize that MMSE is not 
a substitute of a comprehensive cognitive evaluation, in the context of clinical practice it is a useful 
and practical tool to detect those patients that require further cognitive assessment. Furthermore, it 
has been showed by a recent meta-analysis that MMSE is a reasonable tool to detect cognitive 
impairment among cognitive scales for evaluation of stroke patients18. 
The main limitation of the study was the relatively small sample size. Our study may not have the 
statistical power to detect weaker but clinically meaningful associations with cognitive outcomes 
(e.g. SVD markers and cognition). However, the latest systematic review and meta-analysis of 
factors associated with post-stroke dementia examined about 600 patients with MTA assessment and 
found that MTA was associated with an increased risk of both pre- and post-stroke dementia25. 
Although comparable to previous similar studies20,21,24, we acknowledge that the sample size of the 
present was small. Nonetheless, our result considerably expands the dataset of the aforementioned 
meta-analysis, adding more than two hundred stroke patients with standardized MTA and SVD 
ratings. Moreover, the qualitative evaluation of MTA and SVD is easily transferrable to clinical 
practice. 
We acknowledge that we did not included in the analysis important factors associated with post-
stroke cognitive impairment, such as education level and stroke severity. As a retrospective study of 
existing datasets, we were constrained to variables evaluated in the original trials, and education 
level was not routinely assessed in the parent trials. Regarding stroke severity, we inserted in the 
analysis function level after stroke (i.e. disability) as a proxy of stroke severity. The use of a study 
population from clinical trials likely gave us a selected stroke population, however, the advantage of 
using trials dataset is in the quality of the collected data, which is often more complete than clinical 
registries.  
Finally, we underscore that with cognitive data at a single time point we can only describe 
associations between factors of interest. A prospective cohort study could give more information on 
prognosis and possible directions of causation. 
In conclusion, we have demonstrated that MTA, a radiological marker of AD, is frequent among 
stroke survivors and is associated with radiological features of SVD, supporting a substantial overlap 
between vascular and degenerative pathology. Increasing severity of MTA is associated with short to 
medium term post-stroke cognitive impairment, and seems to have more weight than SVD features. 
Careful evaluation of radiological features pertaining to both AD and SVD in patients with stroke 
may help risk stratification for clinical practice and studies. 
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